

Eric J Topol

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3103299/eric-j-topol-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

854
papers

98,774
citations

161
h-index

284
g-index

910
ext. papers

110,911
ext. citations

12.4
avg, IF

8.62
L-index

#	Paper	IF	Citations
854	AI in health and medicine.. <i>Nature Medicine</i> , 2022 ,	50.5	36
853	AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK.. <i>BMJ Open</i> , 2022 , 12, e058552	3	1
852	Impact of polygenic risk communication: an observational mobile application-based coronary artery disease study.. <i>Npj Digital Medicine</i> , 2022 , 5, 30	15.7	5
851	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands.. <i>Npj Digital Medicine</i> , 2022 , 5, 49	15.7	0
850	Passive detection of COVID-19 with wearable sensors and explainable machine learning algorithms. <i>Npj Digital Medicine</i> , 2021 , 4, 166	15.7	7
849	Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening-mHealth Screening to Prevent Strokes (mSToPS). <i>PLoS ONE</i> , 2021 , 16, e0258276	3.7	2
848	Messenger RNA vaccines against SARS-CoV-2. <i>Cell</i> , 2021 , 184, 1401	56.2	20
847	Assessing the human immune response to SARS-CoV-2 variants. <i>Nature Medicine</i> , 2021 , 27, 571-572	50.5	18
846	Conquering Atherosclerotic Cardiovascular Disease - 50 Years of Progress. <i>New England Journal of Medicine</i> , 2021 , 384, 785-788	59.2	8
845	The Physiologic Response to COVID-19 Vaccination 2021 ,		2
844	The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. <i>Annals of Internal Medicine</i> , 2021 , 174, 655-662	8	185
843	Has SARS-CoV-2 reached peak fitness?. <i>Nature Medicine</i> , 2021 , 27, 1323-1324	50.5	13
842	More than meets the eye: Using AI to identify reduced heart function by electrocardiograms.. <i>Med</i> , 2021 , 2, 791-793	31.7	
841	Toward superhuman SARS-CoV-2 immunity?. <i>Nature Medicine</i> , 2021 , 27, 5-6	50.5	8
840	Wearable sensor data and self-reported symptoms for COVID-19 detection. <i>Nature Medicine</i> , 2021 , 27, 73-77	50.5	138
839	What's lurking in your electrocardiogram?. <i>Lancet, The</i> , 2021 , 397, 785	40	1
838	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31

837	Cardiac rehabilitation in the digital era. <i>Lancet, The</i> , 2021 , 398, 16	40	2
836	Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19 Infection. <i>JAMA Network Open</i> , 2021 , 4, e2115959	10.4	16
835	Deep learning-enabled medical computer vision. <i>Npj Digital Medicine</i> , 2021 , 4, 5	15.7	97
834	Is my cough COVID-19?. <i>Lancet, The</i> , 2020 , 396, 1874	40	8
833	Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. <i>BMJ, The</i> , 2020 , 368, m689	5.9	255
832	A brighter future for kidney disease?. <i>Lancet, The</i> , 2020 , 395, 179	40	1
831	Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the USA: a population-based study. <i>The Lancet Digital Health</i> , 2020 , 2, e85-e93	14.4	116
830	Medicine and meteorology: Cloud, connectivity, and care. <i>Lancet, The</i> , 2020 , 395, 1334	40	5
829	Inter- and intraindividual variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time of year: Retrospective, longitudinal cohort study of 92,457 adults. <i>PLoS ONE</i> , 2020 , 15, e0227709	3.7	40
828	Healthcare resource utilization following ECG sensor patch screening for atrial fibrillation. <i>Heart Rhythm O2</i> , 2020 , 1, 351-358	1.5	1
827	Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program. <i>Stem Cell Research</i> , 2020 , 46, 101803	1.6	2
826	Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. <i>Annals of Internal Medicine</i> , 2020 , 173, 362-367	8	1345
825	COVID-19 can affect the heart. <i>Science</i> , 2020 , 370, 408-409	33.3	53
824	Association of Sleep Duration and Variability With Body Mass Index: Sleep Measurements in a Large US Population of Wearable Sensor Users. <i>JAMA Internal Medicine</i> , 2020 , 180, 1694-1696	11.5	15
823	Guiding ultrasound image capture with artificial intelligence. <i>Lancet, The</i> , 2020 , 396, 749	40	11
822	Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist. <i>Nature Medicine</i> , 2020 , 26, 1320-1324	50.5	87
821	Welcoming new guidelines for AI clinical research. <i>Nature Medicine</i> , 2020 , 26, 1318-1320	50.5	27
820	On the Effectiveness of Deep Representation Learning: the Atrial Fibrillation Case. <i>Computer</i> , 2019 , 52, 18-29	1.6	3

819	Digital orthodoxy of human data collection. <i>Lancet, The</i> , 2019 , 394, 556	40	6
818	A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. <i>The Lancet Digital Health</i> , 2019 , 1, e271-e297	144	45 ^o
817	Real world usage characteristics of a novel mobile health self-monitoring device: Results from the Scanadu Consumer Health Outcomes (SCOUT) Study. <i>PLoS ONE</i> , 2019 , 14, e0215468	3.7	7
816	Mechanical activation of noncoding-RNA-mediated regulation of disease-associated phenotypes in human cardiomyocytes. <i>Nature Biomedical Engineering</i> , 2019 , 3, 137-146	19	21
815	A decade of digital medicine innovation. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	46
814	Long data from the electrocardiogram. <i>Lancet, The</i> , 2019 , 393, 2189	40	4
813	Polygenic Risk Scores Expand to Obesity. <i>Cell</i> , 2019 , 177, 518-520	56.2	21
812	Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals. <i>Heart Rhythm</i> , 2019 , 16, 26-30	6.7	12
811	It takes a planet. <i>Nature Biotechnology</i> , 2019 , 37, 858-861	44.5	5
810	What Should Clinicians Do to Engage the Public About Gene Editing?. <i>AMA Journal of Ethics</i> , 2019 , 21, E1089-1097	1.4	
809	Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases. <i>Genome Medicine</i> , 2019 , 11, 83	14.4	22
808	High-performance medicine: the convergence of human and artificial intelligence. <i>Nature Medicine</i> , 2019 , 25, 44-56	50.5	1472
807	Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial. <i>Contemporary Clinical Trials Communications</i> , 2019 , 14, 100318	1.8	11
806	Direct to Consumer Fitness DNA Testing. <i>Clinical Chemistry</i> , 2019 , 65, 45-47	5.5	3
805	Home Monitoring of Blood Pressure: Short-Term Changes During Serial Measurements for 56398 Subjects. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2018 , 22, 1691-1698	7.2	7
804	Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 146-155	27.4	202
803	Analysis of causal effect of APOA5 variants on premature coronary artery disease. <i>Annals of Human Genetics</i> , 2018 , 82, 437-447	2.2	6
802	Validation of a genetic risk score for atrial fibrillation: A prospective multicenter cohort study. <i>PLoS Medicine</i> , 2018 , 15, e1002525	11.6	18

801	Monitoring Jet Engines and the Health of People. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2309-2310	27.4	8
800	Unveiling the Role of the Most Impactful Cardiovascular Risk Locus through Haplotype Editing. <i>Cell</i> , 2018 , 175, 1796-1810.e20	56.2	66
799	Analysis of the 9p21.3 sequence associated with coronary artery disease reveals a tendency for duplication in a CAD patient. <i>Oncotarget</i> , 2018 , 9, 15275-15291	3.3	4
798	The Healthy Pregnancy Research Program: transforming pregnancy research through a ResearchKit app. <i>Npj Digital Medicine</i> , 2018 , 1, 45	15.7	18
797	A skin patch for sensing blood pressures. <i>Nature Biomedical Engineering</i> , 2018 , 2, 633-634	19	5
796	The personal and clinical utility of polygenic risk scores. <i>Nature Reviews Genetics</i> , 2018 , 19, 581-590	30.1	582
795	Digitising the mind. <i>Lancet, The</i> , 2017 , 389, 1877	40	6
794	A Whole Blood Molecular Signature for Acute Myocardial Infarction. <i>Scientific Reports</i> , 2017 , 7, 12268	4.9	27
793	High-Definition Medicine. <i>Cell</i> , 2017 , 170, 828-843	56.2	114
792	Augmenting diagnostic vision with AI. <i>Lancet, The</i> , 2017 , 390, 221	40	19
791	Genome-Wide Linkage Analysis of Large Multiple Multigenerational Families Identifies Novel Genetic Loci for Coronary Artery Disease. <i>Scientific Reports</i> , 2017 , 7, 5472	4.9	10
790	The digitised clinical trial. <i>Lancet, The</i> , 2017 , 390, 2135	40	19
789	Molecular Autopsy for Sudden Death in the Young: Is Data Aggregation the Key?. <i>Frontiers in Cardiovascular Medicine</i> , 2017 , 4, 72	5.4	15
788	Off the cuff: rebooting blood pressure treatment. <i>Lancet, The</i> , 2016 , 388, 749	40	13
787	Digital medicine: empowering both patients and clinicians. <i>Lancet, The</i> , 2016 , 388, 740-1	40	26
786	State of Telehealth. <i>New England Journal of Medicine</i> , 2016 , 375, 154-61	59.2	542
785	To truly look inside. <i>Lancet, The</i> , 2016 , 387, 1268-9	40	9
784	Self-Monitoring Utilization Patterns Among Individuals in an Incentivized Program for Healthy Behaviors. <i>Journal of Medical Internet Research</i> , 2016 , 18, e292	7.6	23

783	A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors. <i>PeerJ</i> , 2016 , 4, e1554	3.1	61
782	A framework for smartphone-enabled, patient-generated health data analysis. <i>PeerJ</i> , 2016 , 4, e2284	3.1	11
781	Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial. <i>American Heart Journal</i> , 2016 , 175, 77-85	4.9	39
780	Whole-Genome Sequencing of a Healthy Aging Cohort. <i>Cell</i> , 2016 , 165, 1002-11	56.2	130
779	Molecular Autopsy for Sudden Unexpected Death. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1492-1494	27.4	24
778	The emerging field of mobile health. <i>Science Translational Medicine</i> , 2015 , 7, 283rv3	17.5	394
777	The big medical data miss: challenges in establishing an open medical resource. <i>Nature Reviews Genetics</i> , 2015 , 16, 253-4	30.1	23
776	Digital medical tools and sensors. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 353-4	27.4	86
775	Moving From Digitalization to Digitization in Cardiovascular Care: Why Is it Important, and What Could it Mean for Patients and Providers?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1489-96	15.1	35
774	Protective alleles and modifier variants in human health and disease. <i>Nature Reviews Genetics</i> , 2015 , 16, 689-701	30.1	75
773	Unpatients-why patients should own their medical data. <i>Nature Biotechnology</i> , 2015 , 33, 921-4	44.5	87
772	A genome sequencing program for novel undiagnosed diseases. <i>Genetics in Medicine</i> , 2015 , 17, 995-1001	18.1	23
771	How Consumers and Physicians View New Medical Technology: Comparative Survey. <i>Journal of Medical Internet Research</i> , 2015 , 17, e215	7.6	27
770	Individualized medicine from prewomb to tomb. <i>Cell</i> , 2014 , 157, 241-53	56.2	194
769	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. <i>Nature</i> , 2014 , 505, 550-554	50.4	345
768	A novel molecular diagnostic marker for familial and early-onset coronary artery disease and myocardial infarction in the LRP8 gene. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 514-20		17
767	Novel wireless devices for cardiac monitoring. <i>Circulation</i> , 2014 , 130, 573-81	16.7	126
766	Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation. <i>Journal of Medical Genetics</i> , 2014 , 51, 83-9	5.8	35

765	Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. <i>Annals of Neurology</i> , 2014 , 75, 542-9	9.4	87
764	Personalized medicine: risk prediction, targeted therapies and mobile health technology. <i>BMC Medicine</i> , 2014 , 12, 37	11.4	60
763	Characteristics of genomic test consumers who spontaneously share results with their health care provider. <i>Health Communication</i> , 2014 , 29, 105-8	3.2	26
762	Can hospital rounds with pocket ultrasound by cardiologists reduce standard echocardiography?. <i>American Journal of Medicine</i> , 2014 , 127, 669.e1-7	2.4	23
761	Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. <i>Physical Biology</i> , 2014 , 11, 016002	3	20
760	Genome-wide linkage scan identifies two novel genetic loci for coronary artery disease: in GeneQuest families. <i>PLoS ONE</i> , 2014 , 9, e113935	3.7	6
759	Implementation of mobile health tools--reply. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1448-9	27.4	
758	Study design and the drug development process. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2023	27.4	2
757	Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. <i>American Journal of Medicine</i> , 2014 , 127, 95.e11-7	2.4	266
756	Multi-allelic haplotype association identifies novel information different from single-SNP analysis: a new protective haplotype in the LRP8 gene is against familial and early-onset CAD and MI. <i>Gene</i> , 2013 , 521, 78-81	3.8	12
755	Rebooting cancer tissue handling in the sequencing era: toward routine use of frozen tumor tissue. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 37-8	27.4	12
754	A call to action: lowering the cost of health care. <i>American Journal of Preventive Medicine</i> , 2013 , 44, S54-61	6.1	11
753	Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. <i>Journal of the American Heart Association</i> , 2013 , 2, e004564	6	35
752	Can mobile health technologies transform health care?. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2395-6	27.4	284
751	Impact of direct-to-consumer genomic testing at long term follow-up. <i>Journal of Medical Genetics</i> , 2013 , 50, 393-400	5.8	108
750	The fibrillin-1 gene: unlocking new therapeutic pathways in cardiovascular disease. <i>Heart</i> , 2013 , 99, 83-90	6.1	13
749	Coronary Artery Disease and Myocardial Infarction 2013 , 516-529		
748	Association of direct-to-consumer genome-wide disease risk estimates and self-reported disease. <i>Genetic Epidemiology</i> , 2012 , 36, 66-70	2.6	14

747	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012 , 33, 2143-50	9.5	73
746	Pharmacogenomics in clinical practice and drug development. <i>Nature Biotechnology</i> , 2012 , 30, 1117-24	44.5	80
745	Cystic fibrosis in an era of genomically guided therapy. <i>Human Molecular Genetics</i> , 2012 , 21, R66-71	5.6	21
744	The unmet need of education in genomic medicine. <i>American Journal of Medicine</i> , 2012 , 125, 5-6	2.4	36
743	Medicine unplugged: the future of laboratory medicine. <i>Clinical Chemistry</i> , 2012 , 58, 1644-7	5.5	18
742	A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) trial. <i>American Heart Journal</i> , 2012 , 164, 320-6	4.9	25
741	Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1928-37	15.1	108
740	Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. <i>American Journal of Human Genetics</i> , 2012 , 91, 823-38	11	189
739	Characterization of circulating endothelial cells in acute myocardial infarction. <i>Science Translational Medicine</i> , 2012 , 4, 126ra33	17.5	58
738	Genetic structure of community acquired methicillin-resistant <i>Staphylococcus aureus</i> USA300. <i>BMC Genomics</i> , 2012 , 13, 508	4.5	18
737	Genome-wide association of implantable cardioverter-defibrillator activation with life-threatening arrhythmias. <i>PLoS ONE</i> , 2012 , 7, e25387	3.7	5
736	Clinical implications of human population differences in genome-wide rates of functional genotypes. <i>Frontiers in Genetics</i> , 2012 , 3, 211	4.5	24
735	CYP2C19 genotype and cardiovascular events. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1482-3; author reply 1484-5	27.4	9
734	Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. <i>Journal of Cardiovascular Translational Research</i> , 2012 , 5, 366-74	3.3	17
733	Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. <i>American Journal of Cardiology</i> , 2012 , 109, 320-6	3	21
732	Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 77-81	6	26
731	Author response to comment on "characterization of circulating endothelial cells in acute myocardial infarction". <i>Science Translational Medicine</i> , 2012 , 4, 149lr4	17.5	2
730	Comment on "the predictive capacity of personal genome sequencing". <i>Science Translational Medicine</i> , 2012 , 4, 135le5; author reply 135lr3	17.5	4

729	Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 265-74	27.4	329
728	Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. <i>Stroke</i> , 2012 , 43, 1058-66	6.7	84
727	Comparative gene expression analysis between coronary arteries and internal mammary arteries identifies a role for the TES gene in endothelial cell functions relevant to coronary artery disease. <i>Human Molecular Genetics</i> , 2012 , 21, 1364-73	5.6	23
726	Response to Letters Regarding Article, Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. <i>Circulation</i> , 2012 , 125	16.7	1
725	Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 138-46	15.1	27
724	The lost decade of nesiritide. <i>New England Journal of Medicine</i> , 2011 , 365, 81-2	59.2	17
723	Effect of direct-to-consumer genomewide profiling to assess disease risk. <i>New England Journal of Medicine</i> , 2011 , 364, 524-34	59.2	459
722	Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2011 , 162, 98-105.e1	4.9	32
721	Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 222-31	3.8	2
720	Annotating individual human genomes. <i>Genomics</i> , 2011 , 98, 233-41	4.3	17
719	Is pocket mobile echocardiography the next-generation stethoscope? A cross-sectional comparison of rapidly acquired images with standard transthoracic echocardiography. <i>Annals of Internal Medicine</i> , 2011 , 155, 33-8	8	115
718	Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. <i>International Journal of Stroke</i> , 2011 , 6, 3-9	6.3	61
717	The importance of phase information for human genomics. <i>Nature Reviews Genetics</i> , 2011 , 12, 215-23	30.1	210
716	9p21 DNA variants associated with coronary artery disease impair interferon- β signalling response. <i>Nature</i> , 2011 , 470, 264-8	50.4	490
715	Digital medicine and the Scripps Translational Science Institute. <i>Clinical and Translational Science</i> , 2011 , 4, 8-9	4.9	1
714	Direct-to-consumer personalized genomic testing. <i>Human Molecular Genetics</i> , 2011 , 20, R132-41	5.6	71
713	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. <i>American Journal of Human Genetics</i> , 2011 , 88, 6-18	11	103
712	Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. <i>BMC Medical Genomics</i> , 2011 , 4, 26	3.7	84

711	Emerging clinical applications in cardiovascular pharmacogenomics. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2011 , 3, 206-15	6.6	6
710	Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. <i>Circulation</i> , 2011 , 124, 1132-7	16.7	331
709	Emerging genomic applications in coronary artery disease. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 473-82	5	30
708	Genomic information as a behavioral health intervention: can it work?. <i>Personalized Medicine</i> , 2011 , 8, 659-667	2.2	43
707	Direct-to-consumer genetic testing: reliable or risky?. <i>Clinical Chemistry</i> , 2011 , 57, 1641-4	5.5	16
706	The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. <i>Personalized Medicine</i> , 2011 , 8, 161-173	2.2	364
705	Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1097-105	27.4	959
704	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. <i>Heart</i> , 2011 , 97, 626-31	5.1	11
703	Bioinformatics, Genomics, and Functional Genomics: Overview 2011 , 567-580		
702	Molecular genetics of atherosclerosis and acute coronary syndromes 2011 , 35-43		
701	Common variants in KCNN3 are associated with lone atrial fibrillation. <i>Nature Genetics</i> , 2010 , 42, 240-4	36.3	362
700	Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study. <i>PLoS Genetics</i> , 2010 , 6, e1001094	6	105
699	A genome-wide linkage scan identifies multiple quantitative trait loci for HDL-cholesterol levels in families with premature CAD and MI. <i>Journal of Lipid Research</i> , 2010 , 51, 1442-51	6.3	9
698	Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress?. <i>Science Translational Medicine</i> , 2010 , 2, 44cm22	17.5	12
697	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>Circulation</i> , 2010 , 121, 2575-83	16.7	173
696	Accurate detection and genotyping of SNPs utilizing population sequencing data. <i>Genome Research</i> , 2010 , 20, 537-45	9.7	84
695	Transforming medicine via digital innovation. <i>Science Translational Medicine</i> , 2010 , 2, 16cm4	17.5	47
694	Genotype-based risk and pharmacogenetic sampling in clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2010 , 20, 315-33	1.3	15

693	A covering method for detecting genetic associations between rare variants and common phenotypes. <i>PLoS Computational Biology</i> , 2010 , 6, e1000954	5	73
692	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2010 , 31, 35-49	9.5	83
691	Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. <i>Stroke</i> , 2010 , 41, 1679-83	6.7	20
690	Consumer perceptions of direct-to-consumer personalized genomic risk assessments. <i>Genetics in Medicine</i> , 2010 , 12, 556-66	8.1	100
689	The case for routine genotyping in dual-antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 109-11	15.1	35
688	Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. <i>American Heart Journal</i> , 2010 , 160, 678-84	4.9	10
687	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2010 , 376, 517-23	40	184
686	Termination of the CRESCENDO trial [Authors' reply]. <i>Lancet, The</i> , 2010 , 376, 1984-1985	40	2
685	Genomics of Myocardial Infarction 2010 , 289-302		
684	Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level. <i>Genome Biology</i> , 2010 , 11, R118	18.3	23
683	Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. <i>Annals of Internal Medicine</i> , 2010 , 153, 425-34	8	136
682	Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INTERvention with Enhanced Reperfusion Speed to Stop Events). <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 203-12	5	32
681	Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 1001-7	5	33
680	The consumer movement in health care. <i>The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha</i> , 2010 , 73, 34-5		1
679	Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. <i>Circulation: Cardiovascular Interventions</i> , 2009 , 2, 503-12	6	21
678	Response to Letter Regarding Article, [Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk] <i>Circulation</i> , 2009 , 119,	16.7	1
677	Sex differences in mortality following acute coronary syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 874-82	27.4	348
676	A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 15483-8	11.5	98

675	Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. <i>Circulation</i> , 2009 , 120, 2337-44	16.7	110
674	Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). <i>American Journal of Cardiology</i> , 2009 , 103, 1359-63	3	90
673	Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 46-53	5	48
672	Microdroplet-based PCR enrichment for large-scale targeted sequencing. <i>Nature Biotechnology</i> , 2009 , 27, 1025-31	44.5	373
671	Human genetic variation and its contribution to complex traits. <i>Nature Reviews Genetics</i> , 2009 , 10, 241-51	30.1	778
670	Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. <i>Value in Health</i> , 2009 , 12, 872-9	3.3	22
669	Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 917-24	5	66
668	1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 909-16	5	48
667	Common vs. rare allele hypotheses for complex diseases. <i>Current Opinion in Genetics and Development</i> , 2009 , 19, 212-9	4.9	490
666	Deficiency of LRP8 in mice is associated with altered platelet function and prolonged time for in vivo thrombosis. <i>Thrombosis Research</i> , 2009 , 123, 644-52	8.2	18
665	Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. <i>American Heart Journal</i> , 2009 , 157, 658-65	4.9	88
664	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , 2009 , 157, 369-74	4.9	63
663	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009 , 157, 818-24, 824.e1	4.9	92
662	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. <i>Archives of Cardiovascular Diseases</i> , 2009 , 102, 485-96	2.7	28
661	The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1935-45	15.1	103
660	Enrichment of sequencing targets from the human genome by solution hybridization. <i>Genome Biology</i> , 2009 , 10, R116	18.3	92
659	Evaluation of next generation sequencing platforms for population targeted sequencing studies. <i>Genome Biology</i> , 2009 , 10, R32	18.3	451
658	Molecular genetics of atrial fibrillation. <i>Genome Medicine</i> , 2009 , 1, 54	14.4	17

657	Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. <i>Annals of Internal Medicine</i> , 2009 , 150, 379-86	8	126
656	The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. <i>European Heart Journal</i> , 2009 , 30, 857-65	9.5	35
655	Patients with peripheral arterial disease in the CHARISMA trial. <i>European Heart Journal</i> , 2009 , 30, 192-201.5	201.5	225
654	Genomics of Myocardial Infarction 2009 , 665-679		
653	Relation between previous lipid-lowering therapy and infarct size (creatin kinase-MB level) in patients presenting with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2008 , 102, 1119-24 ³		5
652	Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). <i>American Journal of Cardiology</i> , 2008 , 102, 1285-90	3	11
651	Study Design and Statistical Issues in Pharmacogenetics Research. <i>Methods in Pharmacology and Toxicology</i> , 2008 , 185-206	1.1	
650	Is computed tomographic angiography prognostic in patients with cardiac symptoms?. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1510; author reply 1510-1	15.1	
649	Genetic determinants of phenotypic diversity in humans. <i>Genome Biology</i> , 2008 , 9, 215	18.3	24
648	The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , 2008 , 155, 687-93	4.9	144
647	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. <i>American Heart Journal</i> , 2008 , 155, 910-7	4.9	35
646	Pathway analysis of seven common diseases assessed by genome-wide association. <i>Genomics</i> , 2008 , 92, 265-72	4.3	279
645	Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1265-76	27.4	393
644	Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. <i>Cerebrovascular Diseases</i> , 2008 , 25, 344-7	3.2	20
643	The use of high-sensitivity assays for C-reactive protein in clinical practice. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 621-35		95
642	Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. <i>Circulation</i> , 2008 , 118, 1705-12	16.7	174
641	Identification of a novel locus for triglyceride on chromosome 1p31-32 in families with premature CAD and MI. <i>Journal of Lipid Research</i> , 2008 , 49, 1034-8	6.3	11
640	Facilitated PCI in patients with ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2008 , 358, 2205-17	59.2	497

639	Mortality, kidney disease and cardiac procedures following acute coronary syndrome. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 934-40	4.3	28
638	Redefining risk in acute coronary syndromes using molecular medicine. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 279-89	15.1	21
637	In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 849-54	15.1	89
636	Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 291-5	15.1	138
635	Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1982-8	15.1	638
634	Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1752-8	15.1	91
633	Future use of genomics in coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1933-40	15.1	49
632	Protein carbamylation links inflammation, smoking, uremia and atherogenesis. <i>Nature Medicine</i> , 2007 , 13, 1176-84	50.5	509
631	Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events. <i>American Journal of Cardiology</i> , 2007 , 100, 227-33	3	23
630	Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. <i>American Journal of Cardiology</i> , 2007 , 100, 1364-9	3	268
629	Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease. <i>Journal of Medical Genetics</i> , 2007 , 44, 161-5	5.8	24
628	Thrombospondins, their polymorphisms, and cardiovascular disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 1886-94	9.4	47
627	Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 1215-22	6.9	12
626	The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2007 , 28, 415-24	9.5	43
625	Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. <i>European Heart Journal</i> , 2007 , 28, 425-32	9.5	16
624	Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. <i>Archives of Internal Medicine</i> , 2007 , 167, 2054-60		55
623	An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. <i>European Heart Journal</i> , 2007 , 28, 2200-7	9.5	60
622	The genomics gold rush. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 218-21	27.4	59

621	A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 2030-6	9.4	126
620	Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. <i>American Heart Journal</i> , 2007 , 153, 36-41	4.9	11
619	Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. <i>American Heart Journal</i> , 2007 , 154, 137-43	4.9	30
618	An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. <i>American Journal of Human Genetics</i> , 2007 , 81, 780-91	11	66
617	Is there a genetic basis for acute coronary syndrome?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, 596-7		1
616	Local Gene and Cell Delivery Devices 2007 , 419-442		
615	The Challenge for Stem Cell Therapy 2007 , 1-6		1
614	βbβ (GPIIb-IIIa) Antagonists 2007 , 1145-1163		5
613	Experimental Antiplatelet Therapy 2007 , 1193-1208		1
612	Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. <i>Free Radical Biology and Medicine</i> , 2006 , 41, 1678-83	7.8	99
611	Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. <i>American Journal of Cardiology</i> , 2006 , 97, 1585-90	3	31
610	Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). <i>American Journal of Cardiology</i> , 2006 , 97, 1591-6	3	29
609	Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2006 , 97, 1679-84	3	1
608	The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice. <i>Catheterization and Cardiovascular Interventions</i> , 2006 , 67, 563-70	2.7	15
607	Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2006 , 68, 352-6	2.7	8
606	Statin use and sex-specific stroke outcomes in patients with vascular disease. <i>Stroke</i> , 2006 , 37, 1427-31	6.7	43
605	Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. <i>European Heart Journal</i> , 2006 , 27, 413-8	9.5	76
604	Genetic susceptibility to myocardial infarction and coronary artery disease. <i>Human Molecular Genetics</i> , 2006 , 15 Spec No 2, R117-23	5.6	140

603	Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 1613-8	9.4	69
602	Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 317, 37-43	4.7	80
601	Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , 2006 , 354, 1706-17	59.2	2120
600	Identification of atherosclerosis-modifying genes: pathogenic insights and therapeutic potential. <i>Expert Review of Cardiovascular Therapy</i> , 2006 , 4, 703-9	2.5	3
599	Aspirin and clopidogrel resistance: an emerging clinical entity. <i>European Heart Journal</i> , 2006 , 27, 647-54	9.5	250
598	The genetics of heart attack. <i>Heart</i> , 2006 , 92, 855-61	5.1	12
597	Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 939-43	15.1	145
596	Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 685-6	15.1	44
595	The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 1567-72	15.1	128
594	Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. <i>American Heart Journal</i> , 2006 , 152, 1051.e9-14	4.9	52
593	Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. <i>American Journal of Medicine</i> , 2006 , 119, 70.e1-8	2.4	48
592	Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. <i>American Journal of Medicine</i> , 2006 , 119, 552-9	2.4	57
591	Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. <i>American Heart Journal</i> , 2006 , 151, 16-24	4.9	19
590	Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. <i>American Heart Journal</i> , 2006 , 152, 157-63	4.9	12
589	Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. <i>American Heart Journal</i> , 2006 , 152, 149-54	4.9	24
588	The prognostic value of the admission and predischARGE electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. <i>American Heart Journal</i> , 2006 , 152, 277-84	4.9	8
587	Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. <i>American Heart Journal</i> , 2006 , 151, 1032.e1-7	4.9	32
586	The genetics of health. <i>Nature Genetics</i> , 2006 , 38, 1095-8	36.3	41

585	A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. <i>Nature Genetics</i> , 2006 , 38, 68-74	36.3	304
584	Integrative medicine: implementation and evaluation of a professional development program using experiential learning and conceptual change teaching approaches. <i>Patient Education and Counseling</i> , 2006 , 62, 5-12	3.1	29
583	The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. <i>Journal of Invasive Cardiology</i> , 2006 , 18, 115-9	0.7	24
582	Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 2245-56	27.4	187
581	Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. <i>European Heart Journal</i> , 2005 , 26, 1283-8	9.5	9
580	Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2005 , 26, 2106-13	9.5	58
579	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2005 , 26, 2396-403	9.5	21
578	Identification of four gene variants associated with myocardial infarction. <i>American Journal of Human Genetics</i> , 2005 , 77, 596-605	11	132
577	A robust hybrid between genetic algorithm and support vector machine for extracting an optimal feature gene subset. <i>Genomics</i> , 2005 , 85, 16-23	4.3	95
576	Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. <i>American Heart Journal</i> , 2005 , 149, 670-4	4.9	78
575	The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. <i>American Heart Journal</i> , 2005 , 149, 869-75	4.9	44
574	The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. <i>American Heart Journal</i> , 2005 , 150, 89-93	4.9	8
573	A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data. <i>American Heart Journal</i> , 2005 , 149, S100-6	4.9	3
572	A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2005 , 150, 401	4.9	27
571	Creation of a large-scale genetic data bank for cardiovascular association studies. <i>American Heart Journal</i> , 2005 , 150, 500-6	4.9	6
570	Outcomes in African Americans and whites after percutaneous coronary intervention. <i>American Journal of Medicine</i> , 2005 , 118, 1019-25	2.4	22
569	Variability in platelet responsiveness to clopidogrel among 544 individuals. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 246-51	15.1	630
568	Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomas to reduced clinical events (REPLACE)-2 trial. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1932-8	15.1	30

567	Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 761-9	15.1	89
566	Simon Dack Lecture. The genomic basis of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1456-65	15.1	44
565	Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. <i>European Heart Journal</i> , 2005 , 26, 2524-8	9.5	21
564	Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. <i>Blood</i> , 2005 , 106, 3970-8	2.2	43
563	Molecular mechanisms of myocardial infarction. <i>Current Problems in Cardiology</i> , 2005 , 30, 333-74	17.1	19
562	Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). <i>American Journal of Cardiology</i> , 2005 , 95, 611-4	3	21
561	Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). <i>American Journal of Cardiology</i> , 2005 , 95, 581-5	3	81
560	Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. <i>American Journal of Cardiology</i> , 2005 , 95, 716-21	3	15
559	Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting. <i>American Journal of Cardiology</i> , 2005 , 95, 791-5	3	24
558	Aspirin resistance and a single gene. <i>American Journal of Cardiology</i> , 2005 , 95, 805-8	3	94
557	Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. <i>American Journal of Cardiology</i> , 2005 , 95, 1218-22	3	267
556	Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. <i>American Journal of Cardiology</i> , 2005 , 95, 1371-5	3	1
555	Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. <i>American Journal of Cardiology</i> , 2005 , 95, 1404-8	3	3
554	Towards precise classification of cancers based on robust gene functional expression profiles. <i>BMC Bioinformatics</i> , 2005 , 6, 58	3.6	118
553	Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. <i>Circulation</i> , 2005 , 112, 906-15; discussion 923	16.7	116
552	Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. <i>Circulation</i> , 2005 , 112, 2812-20	16.7	146
551	Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. <i>FASEB Journal</i> , 2005 , 19, 1893-5	0.9	34
550	Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 2581-6	27.4	411

549	Physicians and the investment industry. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 2654-7	27.4	19
548	Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 1759-65	27.4	457
547	Nesiritide - not verified. <i>New England Journal of Medicine</i> , 2005 , 353, 113-6	59.2	98
546	Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. <i>European Heart Journal</i> , 2005 , 26, 1506-12	9.5	15
545	Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. <i>FASEB Journal</i> , 2005 , 19, 1158-60	0.9	92
544	Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 1584-9	9.4	39
543	Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005 , 10, 209-16	2.6	29
542	Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 45, 61-7	3.1	34
541	Miscues on the "lack of MEF2A mutations" in coronary artery disease. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1399-400; author reply 1400-1	15.9	12
540	Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 1555-62	27.4	725
539	Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2004 , 25, 190-8	9.5	59
538	Failing the public health--rofecoxib, Merck, and the FDA. <i>New England Journal of Medicine</i> , 2004 , 351, 1707-9	59.2	432
537	Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. <i>Circulation</i> , 2004 , 110, 994-8	16.7	134
536	Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. <i>Stroke</i> , 2004 , 35, 528-32	6.7	164
535	Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. <i>Journal of Biological Chemistry</i> , 2004 , 279, 21651-7	5.4	33
534	Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 696-703	27.4	304
533	Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. <i>Circulation</i> , 2004 , 109, 2290-5	16.7	208
532	Transcription factor MEF2A mutations in patients with coronary artery disease. <i>Human Molecular Genetics</i> , 2004 , 13, 3181-8	5.6	85

531	Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 2217-25	27.4	805
530	Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. <i>Circulation</i> , 2004 , 109, 2203-6	16.7	108
529	Risk reduction with long-term clopidogrel following percutaneous coronary intervention. <i>European Heart Journal</i> , 2004 , 25, 2169-70; author reply 2170-1	9.5	5
528	Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. <i>Circulation</i> , 2004 , 110, 1754-60	16.7	59
527	The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. <i>Nature Genetics</i> , 2004 , 36, 233-9	36.3	770
526	Assessing the impact of population stratification on genetic association studies. <i>Nature Genetics</i> , 2004 , 36, 388-93	36.3	623
525	Lack of adverse clopidogrel-atorvastatin clinical interaction. <i>American Journal of Cardiology</i> , 2004 , 93, 669; author reply 669-70	3	1
524	Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). <i>American Journal of Cardiology</i> , 2004 , 93, 458-61	3	20
523	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004 , 93, 679-84	3	104
522	Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). <i>American Journal of Cardiology</i> , 2004 , 93, 1092-6	3	183
521	Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. <i>American Journal of Cardiology</i> , 2004 , 94, 30-4	3	34
520	Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. <i>American Journal of Cardiology</i> , 2004 , 94, 190-2	3	19
519	Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004 , 94, 358-60	3	90
518	Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. <i>American Journal of Cardiology</i> , 2004 , 94, 623-5	3	30
517	Association of race with complications and prognosis following acute coronary syndromes. <i>American Journal of Cardiology</i> , 2004 , 94, 792-4	3	5
516	ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy). <i>American Journal of Cardiology</i> , 2004 , 94, 859-63	3	19
515	Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 63, 135-40	2.7	27
514	Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 542-8	15.1	22

513	Aspirin dose and six-month outcome after an acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 972-8	15.1	42
512	Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 936-42	15.1	86
511	Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1908-14	15.1	77
510	Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIa inhibition versus heparin with routine glycoprotein IIB/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1792-800	15.1	31
509	Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIB/IIIa blockade compared to heparin with routine glycoprotein IIB/IIIa blockade: a REPLACE-2 substudy. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1194-9	15.1	8
508	Coronary artery disease and the thrombospondin single nucleotide polymorphisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2004 , 36, 1013-30	5.6	43
507	First human randomized trial of G-CSF stem cell mobilization to treat large acute myocardial infarction: preliminary results of a pilot study. <i>International Congress Series</i> , 2004 , 1262, 364-367		
506	Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. <i>American Heart Journal</i> , 2004 , 147, 31-4	4.9	38
505	Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. <i>American Heart Journal</i> , 2004 , 147, 246-52	4.9	60
504	Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. <i>American Heart Journal</i> , 2004 , 147, E16	4.9	67
503	Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. <i>American Heart Journal</i> , 2004 , 147, 905-9	4.9	49
502	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2004 , 148, 263-8	4.9	171
501	Impact of female sex on outcome after percutaneous coronary intervention. <i>American Heart Journal</i> , 2004 , 148, 998-1002	4.9	33
500	Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genome-wide linkage analysis. <i>American Journal of Human Genetics</i> , 2004 , 74, 262-71	11	178
499	On the Significance of Linkage Studies of Complex Traits: Reply to Newton-Cheh et al.. <i>American Journal of Human Genetics</i> , 2004 , 75, 152-154	11	3
498	Role of stem cell homing in myocardial regeneration. <i>International Journal of Cardiology</i> , 2004 , 95 Suppl 1, S23-5	3.2	39
497	International differences in evolution of early discharge after acute myocardial infarction. <i>Lancet, The</i> , 2004 , 363, 511-7	4.0	56
496	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. <i>Lancet, The</i> , 2004 , 363, 1139-46	4.0	431

495	Convergence of atherosclerosis and Alzheimer's disease. <i>Lancet, The</i> , 2004 , 363, 2092	40	1
494	A coxib a day won't keep the doctor away. <i>Lancet, The</i> , 2004 , 364, 639-40	40	63
493	Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention Results from the REPLACE-2 trial. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1792-1800	15.1	102
492	An ensemble method for gene discovery based on DNA microarray data. <i>Science in China Series C: Life Sciences</i> , 2004 , 47, 396-405		6
491	Adjunctive therapy for percutaneous revascularization in acute myocardial infarction. <i>Current Pharmaceutical Design</i> , 2004 , 10, 399-405	3.3	8
490	The Cleveland Clinic Foundation interventional summit. <i>Journal of Invasive Cardiology</i> , 2004 , 16, 1S	0.7	
489	Here and now--state of the art: optimal antithrombotic strategy for percutaneous coronary intervention-panel discussion. <i>Journal of Invasive Cardiology</i> , 2004 , 16, 30S-31S	0.7	
488	Genetics of myocardial infarction. <i>Journal of Invasive Cardiology</i> , 2004 , 16, 32S-35S	0.7	
487	The future--panel discussion. <i>Journal of Invasive Cardiology</i> , 2004 , 16, 65S-66S	0.7	
486	Mutation of MEF2A in an inherited disorder with features of coronary artery disease. <i>Science</i> , 2003 , 302, 1578-81	33.3	298
485	International variation in the use of evidence-based medicines for acute coronary syndromes. <i>European Heart Journal</i> , 2003 , 24, 2133-41	9.5	28
484	Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. <i>Circulation</i> , 2003 , 108, 921-4	16.7	216
483	Current status and future prospects for acute myocardial infarction therapy. <i>Circulation</i> , 2003 , 108, 1116-1126	16.7	24
482	Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 2174-81	27.4	150
481	Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry. <i>European Heart Journal</i> , 2003 , 24, 630-8	9.5	8
480	Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. <i>Molecular Therapy</i> , 2003 , 7, 597-603	11.7	39
479	Identification of new genes differentially expressed in coronary artery disease by expression profiling. <i>Physiological Genomics</i> , 2003 , 15, 65-74	3.6	69
478	Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. <i>Physiological Genomics</i> , 2003 , 13, 25-30	3.6	103

477	Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 201-7		45
476	Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. <i>Human Genetics</i> , 2003 , 114, 87-98	6.3	82
475	Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients American Journal of Cardiology, 2003 , 92, 1465-7	3	45
474	Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. <i>American Journal of Cardiology</i> , 2003 , 92, 1468-71	3	15
473	Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survival. <i>American Journal of Cardiology</i> , 2003 , 91, 587-90	3	
472	Relation of insurance status to performance of coronary angiography in patients with unstable angina pectoris or acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 91, 721-3	3	8
471	Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. <i>American Journal of Cardiology</i> , 2003 , 91, 742-3	3	6
470	Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes—observations from the TARGET trial. <i>American Journal of Cardiology</i> , 2003 , 92, 125-9	3	6
469	Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. <i>American Journal of Cardiology</i> , 2003 , 92, 136-40	3	32
468	Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). <i>American Journal of Cardiology</i> , 2003 , 92, 330-3	3	29
467	Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. <i>American Journal of Cardiology</i> , 2003 , 92, 582-3	3	34
466	Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. <i>American Journal of Cardiology</i> , 2003 , 92, 651-5	3	83
465	A matter of life and death? The Heart Protection Study and protection of clinical trial participants. <i>Contemporary Clinical Trials</i> , 2003 , 24, 501-5		5
464	Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. <i>Journal of Interventional Cardiology</i> , 2003 , 16, 299-305	1.8	48
463	Scientific and therapeutic advances in antiplatelet therapy. <i>Nature Reviews Drug Discovery</i> , 2003 , 2, 15-28	4.1	288
462	A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003 , 41, S123-9	15.1	19
461	Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 371-80	15.1	59
460	Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 916-24	15.1	187

459	A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 961-5	15.1	836
458	Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 981-8	15.1	22
457	Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1188-95	15.1	88
456	Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease: Reply. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1336-1337	15.1	20
455	Relation of inflammation and benefit of statins after percutaneous coronary interventions. <i>Circulation</i> , 2003 , 107, 1750-6	16.7	166
454	Preprocedural white blood cell count and death after percutaneous coronary intervention. <i>American Heart Journal</i> , 2003 , 146, 692-8	4.9	44
453	An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial. <i>American Journal of Medicine</i> , 2003 , 114, 106-11	2.4	15
452	Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. <i>American Journal of Medicine</i> , 2003 , 115, 318-21	2.4	20
451	Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. <i>Lancet, The</i> , 2003 , 361, 2017-23	40	852
450	Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. <i>Lancet, The</i> , 2003 , 362, 697-703	40	1080
449	The rudimentary phase of personalised medicine: coronary risk scores. <i>Lancet, The</i> , 2003 , 362, 1776-7	40	30
448	Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. <i>American Heart Journal</i> , 2003 , 145, 515-21	4.9	51
447	Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. <i>American Heart Journal</i> , 2003 , 145, 73-9	4.9	88
446	Prognostic value of myeloperoxidase in patients with chest pain. <i>New England Journal of Medicine</i> , 2003 , 349, 1595-604	59.2	862
445	Clinical trials--multiple treatments, multiple end points, and multiple lessons. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2575-7	27.4	60
444	Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. <i>Circulation</i> , 2003 , 107, 2238-43	16.7	152
443	N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. <i>Circulation</i> , 2003 , 108, 275-81	16.7	470
442	Regionalization of care for acute ischemic heart disease: a call for specialized centers. <i>Circulation</i> , 2003 , 107, 1463-6	16.7	81

441	Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. <i>Circulation</i> , 2003 , 108, 1514-9	16.7	91
440	Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 357-62	9.4	54
439	Prevalence of conventional risk factors in patients with coronary heart disease. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 898-904	27.4	950
438	Critical issues in peripheral arterial disease detection and management: a call to action. <i>Archives of Internal Medicine</i> , 2003 , 163, 884-92		398
437	Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. <i>Circulation</i> , 2003 , 107, 3209-15	16.7	120
436	Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. <i>Journal of Experimental Medicine</i> , 2003 , 197, 615-24	16.6	198
435	Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. <i>Circulation</i> , 2003 , 108, 399-406	16.7	180
434	In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. <i>Archives of Internal Medicine</i> , 2003 , 163, 2576-82		60
433	Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 853-63	27.4	896
432	Anticoagulation with prosthetic cardiac valves. <i>Archives of Internal Medicine</i> , 2003 , 163, 2251-2		5
431	Integrin alphaIIb beta3 and its antagonism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 945-52	9.4	67
430	Recombinant Soluble P-Selectin Glycoprotein Ligand-Ig (rPSGL-Ig) Attenuates Infarct Size and Myeloperoxidase Activity in a Canine Model of Ischemia-Reperfusion. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 149-154	7	29
429	Autologous cell transplantation for the treatment of damaged myocardium. <i>Progress in Cardiovascular Diseases</i> , 2002 , 45, 21-32	8.5	53
428	Pharmacogenomics in cardiovascular diseases. <i>Progress in Cardiovascular Diseases</i> , 2002 , 44, 479-98	8.5	23
427	The role of low-molecular-weight heparin in cardiovascular diseases. <i>Progress in Cardiovascular Diseases</i> , 2002 , 45, 139-56	8.5	12
426	Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002 , 89, 132-6	3	89
425	Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. <i>American Journal of Cardiology</i> , 2002 , 89, 751-3	3	4
424	Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. <i>American Journal of Cardiology</i> , 2002 , 89, 924-9	3	34

423	Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. <i>American Journal of Cardiology</i> , 2002 , 89, 937-40	3	32
422	Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. <i>American Journal of Cardiology</i> , 2002 , 89, 1209-11	3	24
421	Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). <i>American Journal of Cardiology</i> , 2002 , 89, 1429-31	3	6
420	Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). <i>American Journal of Cardiology</i> , 2002 , 90, 42-5	3	148
419	Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. <i>American Journal of Cardiology</i> , 2002 , 90, 625-8	3	314
418	Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. <i>American Journal of Cardiology</i> , 2002 , 90, 628-30	3	12
417	Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). <i>American Journal of Cardiology</i> , 2002 , 90, 916-21	3	29
416	Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. <i>American Journal of Cardiology</i> , 2002 , 90, 1198-203	3	7
415	Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. <i>American Journal of Cardiology</i> , 2002 , 90, 1374-7	3	29
414	Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. <i>Catheterization and Cardiovascular Interventions</i> , 2002 , 57, 476-83	2.7	16
413	Economics and quality of care for patients with acute coronary syndromes: the impending crisis. <i>Clinical Cardiology</i> , 2002 , 25, 19-15	3.3	
412	An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 33-42	5.1	9
411	The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 91-101	5.1	26
410	Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. <i>Annals of Emergency Medicine</i> , 2002 , 39, 123-30	2.1	100
409	Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. <i>Circulation</i> , 2002 , 105, 691-6	16.7	207
408	Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?. <i>Circulation</i> , 2002 , 106, 379-85	16.7	132
407	Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 2411-20	27.4	2289
406	Need to test the arterial inflammation hypothesis. <i>Circulation</i> , 2002 , 106, 136-40	16.7	106

405	Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. <i>Circulation</i> , 2002 , 105, 322-7	16.7	47
404	Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. <i>Circulation</i> , 2002 , 105, 2347-54	16.7	56
403	Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. <i>Annals of Medicine</i> , 2002 , 34, 514-22	1.5	3
402	Aspirin with bypass surgery--from taboo to new standard of care. <i>New England Journal of Medicine</i> , 2002 , 347, 1359-60	59.2	31
401	Genetic testing for coronary heart disease: the approaching frontier. <i>Expert Review of Molecular Diagnostics</i> , 2002 , 2, 448-60	3.8	9
400	Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1598-603	9.4	21
399	Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. <i>Circulation</i> , 2002 , 106, 3063-7	16.7	175
398	Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. <i>Circulation</i> , 2002 , 106, 309-12	16.7	115
397	Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. <i>Circulation</i> , 2002 , 106, 1205-10	16.7	178
396	Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. <i>Circulation</i> , 2002 , 105, 2730-6	16.7	75
395	Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 2130-5	27.4	88
394	Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy). <i>Cardiology</i> , 2002 , 99, 127-30	1.6	6
393	Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. <i>American Journal of Medicine</i> , 2002 , 113, 1-6	2.4	87
392	The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 22-9	15.1	34
391	Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 9-14	15.1	249
390	Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 377-86	15.1	74
389	Prognostic significance of elevated troponin I after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1738-44	15.1	150
388	Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1884-9	15.1	23

387	Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 669-75	15.1	30
386	Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1034-40; discussion 1041-3	15.1	13
385	Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1961-7	15.1	139
384	Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. <i>Atherosclerosis</i> , 2002 , 161, 153-9	3.1	28
383	Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. <i>New England Journal of Medicine</i> , 2002 , 346, 2047-52	59.2	262
382	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. <i>Lancet, The</i> , 2002 , 359, 189-98	40	796
381	Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. <i>Lancet, The</i> , 2002 , 360, 355-60	40	65
380	Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. <i>American Heart Journal</i> , 2002 , 143, 618-22	4.9	59
379	Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. <i>American Heart Journal</i> , 2002 , 143, 594-601	4.9	4
378	Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. <i>American Heart Journal</i> , 2002 , 143, 1040-5	4.9	8
377	Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). <i>American Heart Journal</i> , 2002 , 143, 847-53	4.9	149
376	Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. <i>American Heart Journal</i> , 2002 , 144, 81-8	4.9	50
375	Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). <i>American Heart Journal</i> , 2002 , 144, 995-1002	4.9	41
374	Antiplatelet therapy in cardiology 2002 , 1013-1039		1
373	Lack of cardioprotective effect of naproxen. <i>Archives of Internal Medicine</i> , 2002 , 162, 2637; author reply 2638-9		4
372	Common variations in platelet glycoproteins: pharmacogenomic implications. <i>Pharmacogenomics</i> , 2001 , 2, 341-52	2.6	38
371	Systematic adjudication of myocardial infarction end-points in an international clinical trial. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001 , 2, 180-186		59
370	Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001 , 2, 187-194		65

369	Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001 , 2, 260-262		5
368	Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. <i>American Journal of Cardiology</i> , 2001 , 87, 532-6	3	21
367	Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. <i>American Journal of Cardiology</i> , 2001 , 88, A7, 76-9	3	30
366	Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001 , 88, 124-8	3	69
365	Profile and prevalence of aspirin resistance in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2001 , 88, 230-5	3	672
364	Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. <i>American Journal of Cardiology</i> , 2001 , 88, 672-4	3	127
363	Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2001 , 88, 1403-6, A6	3	25
362	Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes. <i>Progress in Cardiovascular Diseases</i> , 2001 , 44, 195-206	8.5	3
361	Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. <i>Circulation</i> , 2001 , 103, 363-8	16.7	214
360	Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. <i>Circulation</i> , 2001 , 104, 2767-71	16.7	330
359	Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. <i>Circulation</i> , 2001 , 103, 1403-9	16.7	89
358	Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. <i>Circulation</i> , 2001 , 104, 992-7	16.7	202
357	Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. <i>Circulation</i> , 2001 , 104, 2641-4	16.7	247
356	Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. <i>Circulation</i> , 2001 , 104, 815-9	16.7	95
355	beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise. <i>Circulation</i> , 2001 , 104, 2685-8	16.7	30
354	Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. <i>Circulation Research</i> , 2001 , 89, 1-2	15.7	1081
353	Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. <i>Circulation</i> , 2001 , 104, 1229-35	16.7	78
352	Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. <i>Circulation</i> , 2001 , 104, 163-7	16.7	181

351	Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. <i>Circulation</i> , 2001 , 103, 961-6	16.7	299
350	Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. <i>Circulation</i> , 2001 , 103, 2891-6	16.7	178
349	Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. <i>Circulation</i> , 2001 , 104, 2772-7	16.7	31
348	Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. <i>New England Journal of Medicine</i> , 2001 , 344, 1888-94	59.2	555
347	Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 492-8	15.1	27
346	Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Goba Use of Strategies To Open occluded arteries in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1001-7	15.1	23
345	Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 2059-65	15.1	115
344	Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1171-7	15.1	119
343	Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 577-82	15.1	47
342	Oral glycoprotein IIb/IIIa inhibitors: why don't they work?. <i>American Journal of Cardiovascular Drugs</i> , 2001 , 1, 421-8	4	33
341	Acute myocardial infarction after aortic valve endocarditis. <i>American Journal of Medicine</i> , 2001 , 110, 417-8	4	5
340	Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. <i>Circulation</i> , 2001 , 103, 201-6	16.7	309
339	Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. <i>American Heart Journal</i> , 2001 , 141, 469-77	4.9	36
338	Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. <i>American Heart Journal</i> , 2001 , 141, 391-401	4.9	30
337	Recurrent ischemia after thrombolysis for acute myocardial infarction. <i>American Heart Journal</i> , 2001 , 141, 559-65	4.9	9
336	Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. <i>American Heart Journal</i> , 2001 , 141, 599-602	4.9	9
335	Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. <i>American Heart Journal</i> , 2001 , 142, 43-50	4.9	14
334	Recent advances in anticoagulant therapy for acute coronary syndromes. <i>American Heart Journal</i> , 2001 , 142, S22-9	4.9	10

333	Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. <i>American Heart Journal</i> , 2001 , 142, 952-9	4.9	282
332	Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. <i>Lancet, The</i> , 2001 , 357, 1063-8	4.0	247
331	Dosing regimen of reteplase and costeffectiveness. <i>Lancet, The</i> , 2001 , 358, 1462	4.0	
330	ANTIPLATELET AND ANTICOAGULANT THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC HEART DISEASE. <i>Cardiology Clinics</i> , 2001 , 19, 253-265	2.5	
329	Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. <i>Cerebrovascular Diseases</i> , 2000 , 10 Suppl 5, 34-40	3.2	14
328	Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. <i>American Journal of Cardiology</i> , 2000 , 85, 427-34	3	34
327	A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2000 , 85, 692-7	3	13
326	The benefit of abciximab in percutaneous coronary revascularization is not device-specific. <i>American Journal of Cardiology</i> , 2000 , 85, 1060-4	3	27
325	Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. <i>American Journal of Cardiology</i> , 2000 , 86, 780-2, A9	3	83
324	The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome. <i>Clinical Cardiology</i> , 2000 , 23 Suppl 6, VI-23-8	3.3	19
323	Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. <i>Circulation</i> , 2000 , 101, 27-32	16.7	474
322	Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. <i>Circulation</i> , 2000 , 102, 1375-81	16.7	48
321	Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2000 , 9, 741-6		12
320	Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. <i>Circulation</i> , 2000 , 102, 1761-5	16.7	45
319	Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. <i>Circulation</i> , 2000 , 102, 1101-6	16.7	154
318	Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. <i>New England Journal of Medicine</i> , 2000 , 342, 749-55	59.2	107
317	Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. <i>Circulation</i> , 2000 , 102, 728-35	16.7	34
316	Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. <i>Circulation</i> , 2000 , 101, 2557-67	16.7	723

315	Recognition of the importance of embolization in atherosclerotic vascular disease. <i>Circulation</i> , 2000 , 101, 570-80	16.7	634
314	Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. <i>Circulation</i> , 2000 , 101, 751-7	16.7	92
313	Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. <i>Circulation</i> , 2000 , 102, 2923-9	16.7	29
312	Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. <i>Circulation</i> , 2000 , 102, 2952-8	16.7	51
311	Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. <i>Circulation</i> , 2000 , 101, 366-71	16.7	89
310	Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. <i>Circulation</i> , 2000 , 101, 2231-8	16.7	114
309	Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. <i>Circulation</i> , 2000 , 102, 28-34	16.7	51
308	Age and outcome after acute coronary syndromes without persistent ST-segment elevation. <i>American Heart Journal</i> , 2000 , 139, 858-66	4.9	54
307	Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. <i>American Heart Journal</i> , 2000 , 139, 476-81	4.9	32
306	Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. <i>American Journal of Medicine</i> , 2000 , 109, 371-7	2.4	47
305	Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution. <i>American Journal of Medicine</i> , 2000 , 108, 176-7	2.4	9
304	Redefining medical treatment in the management of unstable angina. <i>American Journal of Medicine</i> , 2000 , 108, 41-53	2.4	43
303	Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. <i>American Heart Journal</i> , 2000 , 139, 927-33	4.9	64
302	Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. <i>American Heart Journal</i> , 2000 , 139, 939-44	4.9	35
301	Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators. <i>American Heart Journal</i> , 2000 , 140, 29-33	4.9	4
300	Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. <i>American Heart Journal</i> , 2000 , 140, 74-80	4.9	75
299	Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. <i>American Heart Journal</i> , 2000 , 140, 67-73	4.9	110
298	Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. <i>American Heart Journal</i> , 2000 , 140, 385-94	4.9	19

297	A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. <i>American Heart Journal</i> , 2000 , 140, 722-6	4.9	26
296	New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. <i>American Heart Journal</i> , 2000 , 140, 878-85	4.9	163
295	Importance of microembolization and inflammation in atherosclerotic heart disease. <i>American Heart Journal</i> , 2000 , 140, S90-102	4.9	23
294	Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. <i>Annals of Thoracic Surgery</i> , 2000 , 70, 516-26	2.7	70
293	Cardiogenic shock complicating acute coronary syndromes. <i>Lancet, The</i> , 2000 , 356, 749-56	4.0	144
292	Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. <i>Medical Clinics of North America</i> , 2000 , 84, 163-79, ix	7	24
291	Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1103-15	15.1	164
290	Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1502-12	15.1	67
289	Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 75-83	15.1	91
288	Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. Evaluation of Platelet IIb/IIIa Inhibition for	15.1	115
287	Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 685-92	15.1	99
286	Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1489-96	15.1	140
285	Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 136-43	15.1	102
284	Application of a continuous regression model of restenosis to saphenous vein grafts after successful percutaneous transluminal coronary angioplasty or directional coronary atherectomy. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 619-23	15.1	1
283	Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 563-8	15.1	56
282	Abciximab reduces mortality in diabetics following percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 922-8	15.1	257
281	Strategies to achieve coronary arterial plaque stabilization. <i>Cardiovascular Research</i> , 1999 , 41, 402-17	9.9	90
280	Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. <i>New England Journal of Medicine</i> , 1999 , 341, 319-27	59.2	321

279	Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. <i>Circulation</i> , 1999 , 99, 2371-7	16.7	64
278	Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: An analysis of results from 10,907 lesions and proposal for new classification scheme. <i>Circulation</i> , 1999 , 100, 1971-6	16.7	81
277	Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. <i>Circulation</i> , 1999 , 99, 2892-900	16.7	127
276	Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. <i>Circulation</i> , 1999 , 100, 2477-84	16.7	237
275	Clinical outcomes of bivalirudin for ischemic heart disease. <i>Circulation</i> , 1999 , 100, 2049-53	16.7	86
274	Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. <i>Circulation</i> , 1999 , 100, 1977-82	16.7	97
273	Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. <i>Circulation</i> , 1999 , 100, 2045-8	16.7	246
272	Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. <i>Circulation</i> , 1999 , 99, 370-6	16.7	22
271	Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. <i>Circulation</i> , 1999 , 99, 1951-8	16.7	127
270	One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. <i>Circulation</i> , 1999 , 99, 873-8	16.7	75
269	Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. <i>Circulation</i> , 1999 , 100, 14-20	16.7	462
268	Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. <i>Circulation</i> , 1999 , 100, 2067-73	16.7	173
267	Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. <i>Journal of Thrombosis and Thrombolysis</i> , 1999 , 7, 227-31	5.1	10
266	Reperfusion revisited: beyond TIMI 3 flow. <i>Clinical Cardiology</i> , 1999 , 22, IV20-9	3.3	20
265	Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. <i>American Journal of Cardiology</i> , 1999 , 83, 482-7	3	51
264	Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. <i>American Journal of Cardiology</i> , 1999 , 83, 1147-51	3	105
263	Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. <i>American Journal of Cardiology</i> , 1999 , 84, 728-30, A8	3	25
262	Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. <i>American Journal of Cardiology</i> , 1999 , 84, 779-84	3	64

261	Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. <i>American Journal of Cardiology</i> , 1999 , 84, 1281-6	3	117
260	The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 1269-77	15.1	51
259	Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators. <i>American Heart Journal</i> , 1999 , 137, 227-33	4.9	7
258	Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. <i>American Heart Journal</i> , 1999 , 137, 264-73	4.9	17
257	Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model. <i>International Journal of Cardiology</i> , 1999 , 68 Suppl 1, S85-91	3.2	28
256	Platelet GPIIb-IIIa blockers. <i>Lancet, The</i> , 1999 , 353, 227-31	4.0	446
255	Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. <i>Lancet, The</i> , 1999 , 354, 2019-24	4.0	273
254	Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatid) to Minimize Platelet Aggregation and Coronary Thrombosis-II. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 88-96	15.1	182
253	Effect of age on outcome with primary angioplasty versus thrombolysis. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 412-9	15.1	127
252	The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 647-53	15.1	27
251	Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 1278-85	15.1	
250	Cause of death in clinical research: time for a reassessment?. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 618-20	15.1	493
249	Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 1729-37	15.1	14
248	Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. <i>New England Journal of Medicine</i> , 1999 , 341, 226-32	59.2	641
247	Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. <i>American Heart Journal</i> , 1999 , 138, 976-82	4.9	5
246	Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes. <i>American Heart Journal</i> , 1999 , 138, 1073-81	4.9	29
245	Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. <i>American Heart Journal</i> , 1999 , 138, 493-9	4.9	38
244	Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. <i>American Heart Journal</i> , 1999 , 137, 612-20	4.9	27

243	Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. <i>American Heart Journal</i> , 1999 , 138, 21-31	4.9	140
242	Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. <i>American Heart Journal</i> , 1999 , 137, 799-805	4.9	53
241	Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. <i>American Heart Journal</i> , 1999 , 137, S90-3	4.9	6
240	Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. <i>American Heart Journal</i> , 1999 , 137, 12-23	4.9	11
239	Primary Angioplasty. <i>Contemporary Cardiology</i> , 1999 , 267-291	0.1	1
238	Thrombolytic or Angioplasty Therapy of Evolving Myocardial Infarction? 1998 , 5, S125-S131		1
237	Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 2651-63	1.6	34
236	Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. <i>American Journal of Cardiology</i> , 1998 , 81, 36-40	3	135
235	Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. <i>American Journal of Cardiology</i> , 1998 , 81, 282-7	3	22
234	Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. <i>American Journal of Cardiology</i> , 1998 , 81, 1673-81	3	22
233	Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. <i>American Journal of Cardiology</i> , 1998 , 82, 7-12	3	61
232	Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 1998 , 82, 1105-6, A6	3	6
231	Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). <i>American Journal of Cardiology</i> , 1998 , 82, 63P-68P	3	19
230	Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting. <i>Annals of Emergency Medicine</i> , 1998 , 32, 712-22	2.1	5
229	Coronary stenting and use of abciximab. <i>Lancet, The</i> , 1998 , 352, 1311-1312	4.0	6
228	What role for catheter laboratories in unstable angina?. <i>Lancet, The</i> , 1998 , 352, 500-1	4.0	5
227	Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. <i>Lancet, The</i> , 1998 , 352, 87-92	4.0	538
226	Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 31-6	15.1	44

225	Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 94-102	15.1	19
224	Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 107-110	15.1	106
223	Influence of a randomized clinical trial on practice by participating investigators: lessons from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). CAVEAT I and II Investigators. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 265-72	15.1	12
222	Myonecrosis after revascularization procedures. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 241-51	15.1	367
221	Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 497-505	15.1	47
220	Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1306-13	15.1	11
219	Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1518-24	15.1	75
218	Heparin-induced thrombocytopenia. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1449-59	15.1	169
217	Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1493-8	15.1	82
216	Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1466-73	15.1	145
215	Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 311-9	15.1	129
214	Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 634-40	15.1	110
213	Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 936-41	15.1	26
212	The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 1366-70	15.1	62
211	Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab (GPIIb/IIIa Receptor Blockade). <i>Journal of the American College of Cardiology</i> , 1998 , 32, 1619-23	15.1	110
210	Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 2023-30	15.1	57
209	The future of antithrombotic and antiplatelet therapy for ischemic heart disease. <i>American Heart Journal</i> , 1998 , 136, S66-8	4.9	2
208	Correlates of in-hospital cost among patients undergoing abdominal aortic aneurysm repair. <i>American Heart Journal</i> , 1998 , 136, 696-702	4.9	20

207	Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>American Heart Journal</i> , 1998 , 136, 868-76	4.9	18
206	Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. <i>American Heart Journal</i> , 1998 , 136, 398-405	4.9	48
205	Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. <i>Circulation</i> , 1998 , 98, 734-41	16.7	570
204	Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. <i>Circulation</i> , 1998 , 98, 1860-8	16.7	206
203	Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. <i>Circulation</i> , 1998 , 97, 857-64	16.7	72
202	Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. <i>Circulation</i> , 1998 , 97, 111-50	16.7	63
201	Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. <i>Circulation</i> , 1998 , 97, 211-8	16.7	223
200	Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. <i>Circulation</i> , 1998 , 98, 1376-82	16.7	45
199	Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. <i>Circulation</i> , 1998 , 98, 2567-73	16.7	151
198	Coronary-artery stents--gauging, gorging, and gouging. <i>New England Journal of Medicine</i> , 1998 , 339, 1703-42	16.7	80
197	Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. <i>Circulation</i> , 1998 , 97, 916-31	16.7	887
196	A call for provisional stenting: the balloon is back!. <i>Circulation</i> , 1998 , 97, 1298-305	16.7	76
195	Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. <i>Circulation</i> , 1998 , 97, 1549-56	16.7	127
194	Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. <i>Circulation</i> , 1998 , 98, 1268-78	16.7	86
193	Frontiers in interventional cardiology. <i>Circulation</i> , 1998 , 98, 1802-20	16.7	177
192	Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. <i>Circulation</i> , 1998 , 98, 1853-9	16.7	217
191	Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. <i>Circulation</i> , 1998 , 98, 2829-35	16.7	296
190	The clinical impact of platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular medicine. <i>Japanese Circulation Journal</i> , 1998 , 62, 233-43		5

189	Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of Women's Health</i> , 1997 , 6, 285-93		17
188	Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin B Blockade With Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 1997 , 278, 479	27.4	243
187	Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. <i>American Heart Journal</i> , 1997 , 133, 630-9	4.9	63
186	Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. <i>American Heart Journal</i> , 1997 , 133, 663-73	4.9	80
185	TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. <i>American Heart Journal</i> , 1997 , 133, 273-82	4.9	26
184	Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 259-266	5.1	6
183	Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. <i>Lancet, The</i> , 1997 , 349, 75-8	4.0	81
182	Gender and acute myocardial infarction: is there a different response to thrombolysis?. <i>Journal of the American College of Cardiology</i> , 1997 , 29, 35-42	15.1	124
181	Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1997 , 29, 240-9	15.1	13
180	Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. <i>Journal of the American College of Cardiology</i> , 1997 , 29, 808-16	15.1	233
179	Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 149-56	15.1	179
178	Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 171-9	15.1	337
177	Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 406-13	15.1	319
176	Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 708-15	15.1	133
175	Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 1606-10	15.1	67
174	Clinical trials to prevent restenosis after percutaneous coronary revascularization. <i>Annals of the New York Academy of Sciences</i> , 1997 , 811, 255-84; discussion 284-8	6.5	14
173	A profile of candidates for repeat myocardial revascularization: implications for selection of treatment. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1997 , 114, 153-61	1.5	14
172	Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. <i>American Journal of Cardiology</i> , 1997 , 79, 748-55	3	52

171	Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. <i>American Journal of Cardiology</i> , 1997 , <i>79</i> , 867-72	3	20
170	Late myocardial ischemic events after saphenous vein graft intervention--importance of initially "nonsignificant" vein graft lesions. <i>American Journal of Cardiology</i> , 1997 , <i>79</i> , 1460-4	3	71
169	Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. <i>American Journal of Cardiology</i> , 1997 , <i>80</i> , 985-8	3	103
168	Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. <i>American Journal of Cardiology</i> , 1997 , <i>80</i> , 1075-7	3	23
167	Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. <i>American Journal of Cardiology</i> , 1997 , <i>79</i> , 286-91	3	120
166	Effects of thrombolytic regimen, early catheterization, and predischARGE angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1997 , <i>79</i> , 539-44	3	9
165	Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , <i>4</i> , 325-327	5.1	3
164	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. <i>Catheterization and Cardiovascular Diagnosis</i> , 1997 , <i>42</i> , 102-8		11
163	Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. <i>Circulation</i> , 1997 , <i>95</i> , 2508-16	16.7	143
162	Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. <i>Circulation</i> , 1997 , <i>95</i> , 1072-82	16.7	26
161	Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. <i>Circulation</i> , 1997 , <i>95</i> , 846-54	16.7	276
160	Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. <i>Circulation</i> , 1997 , <i>95</i> , 1300-7	16.7	139
159	First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. <i>Circulation</i> , 1997 , <i>96</i> , 76-81	16.7	81
158	Conjunctive Use of Platelet Glycoprotein IIb/IIIa Antagonists and Thrombolytic Therapy for Acute Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 1997 , <i>78</i> , 214-219	7	21
157	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter 1997 , <i>42</i> , 102		1
156	Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. <i>New England Journal of Medicine</i> , 1996 , <i>335</i> , 1333-41	59.2	919
155	Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. <i>New England Journal of Medicine</i> , 1996 , <i>335</i> , 1198-205	59.2	145
154	Potential value of platelet GPIIb/IIIa antagonist for treating heparin-induced thrombocytopenia (HIT). <i>Journal of the American College of Cardiology</i> , 1996 , <i>27</i> , 316	15.1	7

153	Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 360	15.1	2
152	Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. <i>New England Journal of Medicine</i> , 1996 , 334, 101-7	59.2	446
151	Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 625-32	15.1	95
150	Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 1646-55	15.1	310
149	Another step toward resolving the contrast controversy. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 1387-9	15.1	5
148	Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 106-11	15.1	21
147	Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 305-12	15.1	63
146	Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. <i>American Heart Journal</i> , 1996 , 131, 1097-105	4.9	76
145	Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. <i>American Heart Journal</i> , 1996 , 131, 211-8	4.9	13
144	Cocaine-induced aortic dissection. <i>American Heart Journal</i> , 1996 , 132, 1301-4	4.9	55
143	Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 849-55	15.1	54
142	Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1111-8	15.1	61
141	Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1661-9	15.1	234
140	Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1858-65	15.1	21
139	Role of platelets in restenosis after percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1643-51	15.1	91
138	Risk factors and outcomes in patients with ventricular septal defects (VSD) complicating acute MI. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 67-68	15.1	118
137	Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 83	15.1	9
136	Clinical outcome of High-risk vs Elective patients undergoing percutaneous coronary intervention: Results from IMPACT-II. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 180-181	15.1	2

135	Noninvasive testing is done only in low risk patients with unstable angina and non-Q-wave Myocardial Infarction (MI): Results from GUSTO-IIa. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 181-182	15.1	2
134	Restenosis--an open file. <i>Clinical Cardiology</i> , 1996 , 19, 347-56	3.3	41
133	Antiplatelet and anticoagulant use after myocardial infarction. <i>Clinical Cardiology</i> , 1996 , 19, 357-65	3.3	21
132	Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. <i>American Journal of Cardiology</i> , 1996 , 77, 1045-51	3	183
131	Absence of increased in-hospital complications with reused balloon catheters. <i>American Journal of Cardiology</i> , 1996 , 78, 717-9	3	12
130	Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. <i>American Journal of Cardiology</i> , 1996 , 78, 1338-44	3	3
129	Potential for a New Coronary Thrombolytic Plateau. <i>Journal of Thrombosis and Thrombolysis</i> , 1996 , 3, 127-134	5.1	3
128	The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trials: A Decade of Reperfusion Strategies. <i>Journal of Interventional Cardiology</i> , 1996 , 9, 89-115	1.8	1
127	Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes. <i>Circulation</i> , 1996 , 93, 27-33	16.7	143
126	Analysis and comparison of operator-specific outcomes in interventional cardiology. From a multicenter database of 4860 quality-controlled procedures. <i>Circulation</i> , 1996 , 93, 431-9	16.7	53
125	Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. <i>Circulation</i> , 1996 , 93, 870-8	16.7	179
124	Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. <i>Circulation</i> , 1996 , 94, 2389-95	16.7	25
123	The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. <i>Circulation</i> , 1996 , 94, 3369-75	16.7	85
122	Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. <i>Circulation</i> , 1996 , 94, 629-35	16.7	104
121	One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. <i>Circulation</i> , 1996 , 94, 1233-8	16.7	74
120	Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. <i>Circulation</i> , 1996 , 94, 1528-36	16.7	246
119	Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. <i>Circulation</i> , 1996 , 94, 1690-7	16.7	618
118	Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. <i>Circulation</i> , 1996 , 94, 1826-33	16.7	173

117	Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. <i>Circulation</i> , 1996 , 94, 1927-33	16.7	45
116	Observational versus randomized medical device testing before and after market approval--the atherectomy-versus-angioplasty controversy. <i>Contemporary Clinical Trials</i> , 1995 , 16, 143-9		1
115	Novel antithrombotic approaches to coronary artery disease. <i>American Journal of Cardiology</i> , 1995 , 75, 27B-33B	3	39
114	Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. <i>American Heart Journal</i> , 1995 , 130, 666-72	4.9	26
113	Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1063-8	15.1	113
112	Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) Group. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1007-14	15.1	27
111	Directional atherectomy versus balloon angioplasty for coronary ostial and nonostial left anterior descending coronary artery lesions: results from a randomized multicenter trial. The CAVEAT-I investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1380-6	15.1	26
110	Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1693-9	15.1	121
109	Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 10S-17S	15.1	32
108	Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 668-74	15.1	300
107	Percutaneous revascularization of ostial saphenous vein graft stenoses. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 955-60	15.1	12
106	Evaluation of paradoxical beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 1620-6	15.1	182
105	Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 1651-6	15.1	29
104	901-14 Impact of Ionic and Non-ionic Contrast Media on Post-PTCA Ischemic Complications: Results from the EPIC Trial. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 8A	15.1	6
103	701-6 Dissociation Between Minimal Luminal Diameter and Clinical Outcome at 6 Month Follow-up in Randomized Trials of Percutaneous Revascularization. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 36A	15.1	3
102	711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 21A	15.1	19
101	Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>New England Journal of Medicine</i> , 1995 , 333, 565-72	59.2	304
100	Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. <i>New England Journal of Medicine</i> , 1995 , 332, 1418-24	59.2	460

99	Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. <i>New England Journal of Medicine</i> , 1995 , 332, 1553-9	59.2	665
98	Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). <i>Journal of the American College of Cardiology</i> , 1995 , 26, 922-30	15.1	95
97	Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. <i>American Journal of Cardiology</i> , 1995 , 76, 1007-13	3	32
96	Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 1995 , 76, 1222-7	3	184
95	Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. <i>American Journal of Cardiology</i> , 1995 , 75, 559-62	3	140
94	Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. <i>American Journal of Cardiology</i> , 1995 , 75, 871-6	3	72
93	Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. <i>Circulation</i> , 1995 , 91, 2733-41	16.7	48
92	Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. <i>Circulation</i> , 1995 , 91, 2882-90	16.7	189
91	Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. <i>Circulation</i> , 1995 , 91, 298-303	16.7	124
90	Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. <i>Circulation</i> , 1995 , 91, 1659-68	16.7	704
89	Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. <i>Circulation</i> , 1995 , 91, 1923-8	16.7	343
88	A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. <i>Circulation</i> , 1995 , 91, 1966-74	16.7	134
87	Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. <i>Circulation</i> , 1995 , 91, 2151-7	16.7	207
86	One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). <i>Circulation</i> , 1995 , 91, 2158-66	16.7	77
85	Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. <i>Circulation</i> , 1995 , 92, 2811-8	16.7	192
84	Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. <i>Circulation</i> , 1995 , 92, 2825-30	16.7	244
83	Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. <i>Circulation</i> , 1995 , 92, 3041-50	16.7	110
82	Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. <i>Circulation</i> , 1995 , 92, 492-9	16.7	39

81	Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. <i>Circulation</i> , 1995 , 92, 734-40	16.7	72
80	In-hospital cost of percutaneous coronary revascularization. Critical determinants and implications. <i>Circulation</i> , 1995 , 92, 741-7	16.7	58
79	Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. <i>Circulation</i> , 1995 , 92, 2333-42	16.7	751
78	Effects of antisense c-myc oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. <i>Circulation Research</i> , 1995 , 76, 505-13	15.7	93
77	More on the GUSTO trial. <i>New England Journal of Medicine</i> , 1994 , 331, 277-8	59.2	32
76	Pathology of Unstable Angina: Analysis of Biopsies Obtained by Directional Coronary Atherectomy. <i>Journal of Thrombosis and Thrombolysis</i> , 1994 , 1, 63-71	5.1	9
75	Comparison of three coronary stents: clinical and angiographic outcome after elective placement in 134 consecutive patients. <i>Catheterization and Cardiovascular Diagnosis</i> , 1994 , 33, 199-204		18
74	Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. <i>American Journal of Cardiology</i> , 1994 , 74, 1166-70	3	88
73	Cell adhesion molecules in coronary artery disease. <i>Journal of the American College of Cardiology</i> , 1994 , 24, 1591-601	15.1	337
72	Randomized trials of directional coronary atherectomy: implications for clinical practice and future investigation. <i>Journal of the American College of Cardiology</i> , 1994 , 24, 431-9	15.1	31
71	Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 891-8	15.1	53
70	Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. <i>New England Journal of Medicine</i> , 1994 , 331, 1130-5	59.2	269
69	Semantic ambiguity, the "non-" nosology and myocardial infarction. <i>Journal of Clinical Epidemiology</i> , 1994 , 47, 441-6	5.7	3
68	Scorecard cardiovascular medicine. Its impact and future directions. <i>Annals of Internal Medicine</i> , 1994 , 120, 65-70	8	84
67	The restenosis "antitheory". <i>Mayo Clinic Proceedings</i> , 1993 , 68, 88-90	6.4	7
66	Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 381-9	15.1	283
65	Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. <i>Journal of the American College of Cardiology</i> , 1993 , 21, 622-7	15.1	162
64	Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study. <i>Journal of the American College of Cardiology</i> , 1993 , 21, 866-75	15.1	117

63	Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. <i>Journal of the American College of Cardiology</i> , 1993 , 21, 920-5	15.1	233
62	Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. <i>Journal of the American College of Cardiology</i> , 1993 , 21, 1539-49	15.1	242
61	Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty? Multivessel Angioplasty Prognosis Study (MAPS) Group. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 1289-97	15.1	48
60	Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 1780-7	15.1	94
59	Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 135-43	15.1	320
58	A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. <i>New England Journal of Medicine</i> , 1993 , 329, 221-7	59.2	590
57	An analysis of the cause of early mortality after administration of thrombolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group. <i>Coronary Artery Disease</i> , 1993 , 4, 957-64 ^{1,4}		26
56	Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. <i>Coronary Artery Disease</i> , 1993 , 4, 167-75	1.4	58
55	Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy. <i>American Journal of Cardiology</i> , 1993 , 71, 552-7	3	34
54	Results of directional coronary atherectomy during multicenter preapproval testing. The US Directional Coronary Atherectomy Investigator Group. <i>American Journal of Cardiology</i> , 1993 , 72, 6E-11E ³		29
53	Clinical Trials of Platelet Receptor Inhibitors. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 094-098	7	38
52	Should older patients with acute myocardial infarction receive thrombolytic therapy?. <i>Drugs and Aging</i> , 1992 , 2, 461-8	4.7	6
51	Thrombolytic therapy for acute myocardial infarction. A review. <i>Drugs</i> , 1992 , 44, 293-325	12.1	114
50	Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 482-9	15.1	62
49	Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 647-53	15.1	96
48	Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 926-35	15.1	298
47	Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 1123-8	15.1	41
46	Experimental models of coronary artery restenosis. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 418-32	15.1	205

45	Abrupt vessel closure after directional coronary atherectomy. The U.S. Directional Atherectomy Investigator Group. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 1372-9	15.1	39
44	Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. <i>American Journal of Cardiology</i> , 1992 , 69, 63-8	3	232
43	Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings. <i>American Journal of Cardiology</i> , 1991 , 67, 431-3	3	63
42	Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settings. <i>American Journal of Cardiology</i> , 1991 , 68, 1447-51	3	60
41	In-hospital costs associated with new percutaneous coronary devices. <i>American Journal of Cardiology</i> , 1991 , 68, 879-85	3	62
40	Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. <i>American Journal of Cardiology</i> , 1991 , 67, 225-30	3	83
39	The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. <i>American Heart Journal</i> , 1991 , 121, 895-901	4.9	96
38	Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. <i>American Heart Journal</i> , 1991 , 122, 943-8	4.9	79
37	Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. <i>Journal of the American College of Cardiology</i> , 1991 , 18, 1077-84	15.1	115
36	Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. <i>Journal of the American College of Cardiology</i> , 1991 , 17, 89B-95B	15.1	56
35	Coronary angiography after thrombolytic therapy for acute myocardial infarction. <i>Annals of Internal Medicine</i> , 1991 , 114, 877-85	8	44
34	Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 1991 , 65, 275-279	7	42
33	Results of percutaneous transluminal coronary angioplasty of high-risk angulated stenoses. <i>American Journal of Cardiology</i> , 1990 , 66, 932-7	3	31
32	Acute intervention during myocardial infarction in patients with prior coronary bypass surgery. <i>American Journal of Cardiology</i> , 1990 , 65, 924-6	3	14
31	Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute myocardial infarction. TAMI Study Group. <i>Catheterization and Cardiovascular Diagnosis</i> , 1990 , 20, 221-6		5
30	One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. <i>American Heart Journal</i> , 1990 , 119, 777-85	4.9	23
29	Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. <i>Journal of the American College of Cardiology</i> , 1990 , 16, 770-8	15.1	116
28	Initial report of the National Registry of Elective Cardiopulmonary Bypass Supported Coronary Angioplasty. <i>Journal of the American College of Cardiology</i> , 1990 , 15, 23-9	15.1	135

27	Emergency percutaneous transluminal coronary angioplasty during acute myocardial infarction for patients more than 70 years of age. <i>American Journal of Cardiology</i> , 1989 , 63, 399-403	3	38
26	Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1989 , 13, 1251-9	15.1	62
25	From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. <i>Journal of the American College of Cardiology</i> , 1989 , 14, 1382-8	15.1	132
24	Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. <i>Journal of the American College of Cardiology</i> , 1989 , 14, 877-84	15.1	91
23	Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. <i>Journal of the American College of Cardiology</i> , 1989 , 13, 12-8	15.1	87
22	Determinants of Left Ventricular Functional Recovery After Thrombolytic Therapy and/or Immediate Coronary Angioplasty in Acute Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 1988 , 1, 167-174	1.8	1
21	Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. <i>American Heart Journal</i> , 1988 , 115, 1-7	4.9	55
20	Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. <i>American Journal of Medicine</i> , 1988 , 85, 353-9	2.4	150
19	Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1988 , 11, 899-907	15.1	37
18	Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. <i>Journal of the American College of Cardiology</i> , 1988 , 12, 24A-31A	15.1	56
17	Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1988 , 12, 58A-68A	15.1	17
16	Predictors of success for coronary angioplasty performed for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1988 , 12, 1407-15	15.1	40
15	A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. <i>New England Journal of Medicine</i> , 1988 , 318, 1083-8	59.2	164
14	A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. <i>New England Journal of Medicine</i> , 1987 , 317, 1613-8	59.2	330
13	A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. <i>New England Journal of Medicine</i> , 1987 , 317, 581-8	59.2	860
12	Advances in thrombolytic therapy for acute myocardial infarction. <i>Journal of Clinical Pharmacology</i> , 1987 , 27, 735-45	2.9	13
11	Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. <i>Journal of the American College of Cardiology</i> , 1987 , 10, 1173-7	15.1	75
10	Multicenter study of percutaneous transluminal angioplasty for right coronary artery ostial stenosis. <i>Journal of the American College of Cardiology</i> , 1987 , 9, 1214-8	15.1	144

9	Exercise testing three days after onset of acute myocardial infarction. <i>American Journal of Cardiology</i> , 1987 , 60, 958-62	3	27
8	Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. <i>American Journal of Cardiology</i> , 1987 , 59, 513-5	3	145
7	Applicability of percutaneous transluminal coronary angioplasty to patients with recombinant tissue plasminogen activator mediated thrombolysis. <i>Catheterization and Cardiovascular Diagnosis</i> , 1985 , 11, 337-48		15
6	Selection of dilatation hardware for PTCA--1985. <i>Catheterization and Cardiovascular Diagnosis</i> , 1985 , 11, 629-37		19
5	Passive Monitoring of Physiological Data and Self-reported Symptoms to Detect Clusters of People with COVID-19		2
4	Moving Beyond Clinical Risk Scores with a Mobile App for the Genomic Risk of Coronary Artery Disease		5
3	The Healthy Pregnancy Research Program: Transforming Pregnancy Research Through a ResearchKit App		1
2	A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors		2
1	Response to Polygenic Risk: Results of the MyGeneRank Mobile Application-Based Coronary Artery Disease Study		1